Evidence · Research paper
Dexamethasone, Prednisolone, and Methylprednisolone Use and 2-Year Neurodevelopmental Outcomes in Extremely Preterm Infants.
- Anaemia and transfusion
- Bronchopulmonary dysplasia
- Jaundice and haematology
- Medical
- Neurodevelopmental follow-up
- Neurology
- Respiratory
Summary
Secondary cohort analysis of the US PENUT trial describing postnatal corticosteroid use (dexamethasone, prednisolone, methylprednisolone) in extremely preterm infants born at 24-27 weeks' gestation for prevention or treatment of bronchopulmonary dysplasia. It evaluates associations between cumulative dose and duration of exposure and Bayley-III neurodevelopmental scores at 2 years corrected age. Longer and higher cumulative dexamethasone exposure was associated with poorer motor and language scores, though residual confounding by illness severity is acknowledged. The authors call for standardised treatment and documentation of indications.
Summary written for NICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to NICUlearn members, and Neeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.